13Jul 2023
From mucosal infection to successful cancer immunotherapy

From mucosal infection to successful cancer immunotherapy

Immune checkpoint blockers (ICBs) have transformed the clinical management of advanced urinary tract malignancies. Research focuses on identifying beneficial tumor antigens and natural adjuvants. Recent evidence suggests that urinary or intestinal commensal bacteria, such as BCG and uropathogenic Escherichia coli, influence long-term responses in kidney or bladder cancer patients treated with ICBs. The presence of these bacteria in the urothelium may activate T follicular helper cells and B cells, bridging innate and CD8+ memory responses.

  • #urology

Like

Save

Share